Drug Information

Drug General Information
Drug ID
D06UWF
Former ID
DIB001115
Drug Name
SOR-C13
Indication Ovarian cancer [ICD9: 183; ICD10:C56] Phase 1 [523872]
Company
Soricimed biopharma
Target and Pathway
Target(s) Transient receptor potential channel 6, subfamily V Target Info Inhibitor [532294]
KEGG Pathway Salivary secretion
Mineral absorption
NetPath Pathway IL2 Signaling Pathway
Pathway Interaction Database TCR signaling in na&#xef
Signaling events mediated by PTP1B
TCR signaling in na&#xef
Reactome TRP channels
WikiPathways Vitamin D Receptor Pathway
miR-targeted genes in lymphocytes - TarBase
References
Ref 523872ClinicalTrials.gov (NCT01578564) Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel. U.S. National Institutes of Health.
Ref 532294In vivo detection of human TRPV6-rich tumors with anti-cancer peptides derived from soricidin. PLoS One. 2013;8(3):e58866.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.